

DAFTAR PUSTAKA

1. Artono, Surarto B, Purnami N, Hutahaen F, Mahardhika MR. The Association of IL-1 Alpha Level and TNF Alpha Expressions on Bone Destruction in Chronic Suppurative Otitis Media and Cholesteatoma. *Indian J Otolaryngol Head Neck Surg.* 2020;72(1):1–7.
2. Edward Y, Decroli E, Ali H, Tjong DH. Expression of ccl27 in middle ear cholesteatoma. *Open Access Maced J Med Sci.* 2021;9(T3):240–3.
3. Hamed MA, Nakata S, Sayed RH, Ueda H, Badawy BS, Nishimura Y, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future prospectives. *Clin Exp Otorhinolaryngol.* 2016;9(4):298–308.
4. Westerberg J. Middle Ear Cholesteatoma Surgical Outcome and Aspects of The Innate Immunity (dissertation). Linköping University Medical; 2020.
5. Macias JD, Gerkin RD, Locke D, Macias MMP. Differential gene expression in cholesteatoma by DNA chip analysis. *Laryngoscope.* 2013;123(SUPPL.5):1–21.
6. Karakawa M, Komine M, Hanakawa Y, Tsuda H, Sayama K, Tamaki K, et al. CCL27 is downregulated by interferon gamma via epidermal growth factor receptor in normal human epidermal keratinocytes. *J Cell Physiol.* 2014;229(12):1935–45.
7. Pivarsci A, Müller A, Hippe A, Rieker J, Van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. *Proc Natl Acad Sci U S A.* 2007;104(48):19055–60.
8. Menglu Z, Yongtuan L. Expression of chemokine ligand 27 in secondary middle ear cholesteatoma. *J Shandong Univ (Otolaryngology Ophtalmol.* 2017;31(6):46–8.
9. Qurniawan, RM. Perbedaan Ekspresi Gen Epidermal Growth Factor Receptor dan C-C Motif Chemokine Ligand 27 Antara Kolesteatoma Dengan Kulit Telinga Normal Pada Penderita Otitis Media Supuratif Kronis (tesis). Universitas Andalas; 2022.
10. Wardhana, Made. Suryawati, Nyoman. Praharsini HIEI. Hubungan Antara Kadar Serum Interferon Gamma Dengan Derajat Keparahan Psoriasis Vulgaris. *Media Dermato-Venereologica Indones.* 2018;45(4):178–81.
11. Kurtovic NO, Halilovic EK. Serum Concentrations of Interferon Gamma (IFN- γ) in Patients with Psoriasis: Correlation with Clinical Type and Severity of the Disease. *Med Arch (Sarajevo, Bosnia Herzegovina).* 2018;72(6):410–3.
12. Yung M, Tono T, Olszewska E, Yamamoto Y, Sudhoff H, Sakagami M, et al. EAONO/JOS joint consensus statements on the Definitions, Classification and Staging of Middle Ear Cholesteatoma. *J Int Adv Otol.* 2017;13(1):1–8.
13. Hellier WP. Chronic Otitis Media. In: Watkinson JC, editor. *Scott Brown's Otorhinolaryngology Head and Neck Surgery.* Eighth. New York: Taylor & Francis; 2018. p. 155–63.
14. Castle JT. Cholesteatoma Pearls: Practical Points and Update. *Head Neck*

- Pathol. 2018;12(3):419–29.
15. Gilberto N, Custódio S, Colaço T, Santos R, Sousa P, Escada P. Middle ear congenital cholesteatoma: systematic review, meta-analysis and insights on its pathogenesis. *Eur Arch Oto-Rhino-Laryngology*. 2020;277(4):987–98.
 16. Cantone E, Di Nola C, De Corso E, Cavaliere M, Grimaldi G, Fetoni AR, et al. Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review. *J Pers Med*. 2022;12(8):1–11.
 17. Indriani I, Edward Y, Rosalinda R. Kolesteatom Kongenital dengan Komplikasi Abses Retroaurikula. *J Kesehat Andalas*. 2020;9(2):262.
 18. Richard A. Chole JDS. Chronic Otitis Media, Mastoiditis and Petrositis. In: Cummings Otolaryngology-Head & Neck Surgery. seventh. Philadelphia; 2021. p. 2118–33.
 19. Ted A, Meyer. Chester L, Stunk Jr. Paul R L. Cholesteatoma. In: Bailey's Head and Neck Surgery Otolaryngology. 2014. p. 2433–44.
 20. Kuo C-L. Recent Advances in Understanding the Pathogenesis of Acquired Cholesteatoma. *Recent Adv Otolaryngol Neck Surg (Volume 5)*. 2016;(May):167–167.
 21. Rutkowska J, Özgirgin N, Olszewska E. Cholesteatoma definition and classification: A literature review. *J Int Adv Otol*. 2017;13(2):266–71.
 22. Kuo CL. Etiopathogenesis of acquired cholesteatoma: Prominent theories and recent advances in biomolecular research. *Laryngoscope*. 2015;125(1):234–40.
 23. Jackler RK, Santa Maria PL, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. *Laryngoscope*. 2015;125(S4):S1–14.
 24. Munilson J, Edward Y, Dwita LF, Ali H. Expression of cytokeratin 6 and 16 in middle ear cholesteatoma. *Open Access Maced J Med Sci*. 2021;9(B):1323–8.
 25. Prinsley P. The genetics of Cholesteatoma (dissertation). University of East Anglia; 2018.
 26. Wageih Felfela GM. Ear Anatomy. *Glob J Otolaryngol*. 2017;4(1):22–39.
 27. EI-Naggar A.K., Chan J.K.C., Grandis J.R., Takata T. SP. WHO classification of head and neck tumors 2017. In: WHO classification of Head and neck Tumors 2017. 4th ed. 2017. p. 47–9.
 28. Lim HD, Robert Lane J, Canals M, Stone MJ. Systematic assessment of chemokine signaling at chemokine receptors ccr4, ccr7 and ccr10. *Int J Mol Sci*. 2021;22(8).
 29. Irwandanon I, Edwar Y, Munilson J, Ali H. The expression of receptor activator of nuclear factor $\kappa\beta$ ligand and osteoprotegerin of cholesteatoma in Padang, West Sumatra, Indonesia. *Ed Minerva Medica Otorinolaringol J*. 2020;70(1):1–5.
 30. Azizah N, Edward Y, Munilson J. Ekspresi Matrix Metalloproteinase-9 dan Tissu Inhibitor of Metalloproteinase-1 pada Kolesteatoma Penderita Otitis Media Supuratif Kronis (tesis). Universitas Andalas; 2017.
 31. Sitompul BP, H EH, Sp THTKLK. Laporan Kasus Kolesteatoma Kongenital pada Atresia Canalis Acousticus Externus Kongenital Unilateral dan Mikrotia Grade I. *Malang Otorhinolaryngol Head Neck Surg*. 2023;2(1):1–6.

32. Kanemaru SI, Kikkawa Y, Omori K, Ito J. Bone destructive mechanisms of cholesteatoma. *Laryngoscope*. 2010;120(SUPPL. 3):68.
33. Xie S, Wang X, Ren J, Liu W. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. *Eur Arch Oto-Rhino-Laryngology*. 2017;274(5):2071–8.
34. Maniu A, Harabagiu O, Schrepler MP, Cătană A, Fănuță B, Mogoantă CA. Molecular biology of cholesteatoma. *Rom J Morphol Embryol*. 2014;55(1):7–13.
35. Edward Y, Munilson J, Rosalinda R, Ali H, Irfandy D, Swanda D. Expression of tumor necrosis factor- α and interleukin-6 in chronic suppurative otitis media. *Turkish J Immunol*. 2019;7(1):1–5.
36. Schürmann M, Oppel F, Shao S, Volland-Thurn V, Kaltschmidt C, Kaltschmidt B, et al. Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism. *Cell Commun Signal*. 2021;19(1):1–15.
37. Wiatr A, Streck P, Wiatr M. Patterns of Bone Damage in Patients With Chronic Middle Ear Inflammation. *Ear, Nose Throat J*. 2021;100(10):NP438–43.
38. Mansour, Salah, Magnan, Jacques,, Karen, Nicolas,, Haidar H. Middle ear disease. In: *Middle Ear Disease*. Springer; 2018. p. 311–81.
39. Novianti D, Edward Y, Munilson J. Perbedaan Frekuensi Pembentukan Biofilm Bakteri Aerob pada Otitis Media Supuratif Kronis Tipe Aman Fase Aktif dengan Tipe Bahaya di RSUP dr. M Djamil Padang (tesis). Universitas Andalas; 2016.
40. Lestari DY, Edward Y, Munilson J. Perbedaan Kadar Lipopolisakarida Antara Otitis Media Supuratif Kronis Tipe Bahaya dengan Tipe Aman Fase Aktif (tesis). Universitas Andalas; 2018.
41. L. Ferreira V, H.L. Borba H, de F. Bonetti A, P. Leonart L, Pontarolo R. Cytokines and Interferons: Types and Functions. In: *Autoantibodies and Cytokines*. IntechOpen; 2019. p. 65–87.
42. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN- γ): Exploring its implications in infectious diseases. *Biomol Concepts*. 2018;9(1):64–79.
43. Ivanova N, Gugleva V, Dobрева M, Pehlivanov I, Stefanov S, Andonova V. Basic and Clinical Aspects of Interferon Gamma. In: Hridayesh Prakash, editor. *Intech*. 2022. p. 1–25.
44. Bae H, Barlow AT, Young H, Valencia JC. Interferon γ : An Overview of Its Functions in Health and Disease. Vol. 2, *Encyclopedia of Immunobiology*. Elsevier; 2016. 494–500 p.
45. Bhat MY, Solanki HS, Advani J, Khan AA, Keshava Prasad TS, Gowda H, et al. Comprehensive network map of interferon gamma signaling. *J Cell Commun Signal*. 2018;12(4):745–51.
46. Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X, et al. Activation of the EGFR/Akt/NF- κ B/cyclinD1 survival signaling pathway in human cholesteatoma epithelium. *Eur Arch Oto-Rhino-Laryngology*. 2014;271(2):265–73.
47. Kaya İ, Avcı ÇB, Şahin FF, Özateş NP, Sezgin B, Kurt CÇ, et al. Evaluation of significant gene expression changes in congenital and acquired

- cholesteatoma. *Mol Biol Rep.* 2020;47(8):6127–33.
48. Dahlan MS. Menentukan Rumus Besar Sampel. In: Suslia A, editor. *Besar Sampel dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan.* 3rd ed. Salemba Medika; 2010. p. 19–23.
 49. Im GJ, do Han K, Park KH, Cho CH, Jang H, Lee JH, et al. Rate of chronic otitis media operations and cholesteatoma surgeries in South Korea: a nationwide population-based study (2006–2018). *Sci Rep.* 2020;10(1):1–10.
 50. Rosito LPS, da Silva MNL, Selaimen FA, Jung YP, Pauletti MGT, Jung LP, et al. Características de 419 pacientes com colesteatoma adquirido de orelha média. *Braz J Otorhinolaryngol.* 2017;83(2):126–31.
 51. Mahajan T, Dass A, Gupta N, Chander J, Saini V, Pol SA. Bacteriological Profile in Attico-antral type of Chronic Suppurative Otitis Media. *Indian J Otolaryngol Head Neck Surg.* 2019;71(s2):1412–21.
 52. Alhazmi WA, Al Mansour MH, Aljasser RI, Alanazi AM, Alyami SD, Almutairi AB, et al. A Brief Review of Demographic and Clinical Correlates of Cholesteatoma Surgery in the Qassim Region. *Cureus.* 2023;15(3):e35676.
 53. Møller PR, Pedersen CN, Grosfjeld LR, Faber CE, Djurhuus BD. Recurrence of cholesteatoma - A retrospective study including 1,006 patients for more than 33 years. *Int Arch Otorhinolaryngol.* 2020;24(1):E18–23.
 54. Keita A, Diallo I, Diallo MA, Diallo MMR, Fofana M, Barry K, et al. Cholesteatoma of the middle ear: about 50 cases in Donka University Hospital. *Int J Otorhinolaryngol Head Neck Surg.* 2022;8(10):787.
 55. Alhomsy K. Cholesteatoma Effects on Hearing and Ossicles at Al-Mouwasat University Hospital Cholesteatoma Effects on Hearing and Ossicles at Al-Mouwasat University Hospital Khaled Alhomsy. 2020;(December):14–9.
 56. Handoko E, Indrasworo D, Nursalim AH. Hubungan Derajat Kolesteatoma dengan Keberhasilan Mastoidektomi Radikal pada Otitis Media Supuratif Kronis dengan Kolesteatoma. *Oto Rhino Laryngol Indones.* 2019;49(2):99.
 57. Shwetha. Chronic otitis media with cholesteatoma: clinical presentation and surgical management. *Int J Otorhinolaryngol Head Neck Surg.* 2018;4(5):1212.
 58. Topik MM, Tacha N. Penatalaksanaan Psoriasis Terkini. *J Ilmu Kedokt dan Kesehat Indones.* 2023;3(3):134–56.
 59. Das P, Mounika P, Yellurkar ML, Prasanna VS, Sarkar S, Velayutham R, et al. Keratinocytes: An Enigmatic Factor in Atopic Dermatitis. *Cells.* 2022;11(10).
 60. Noor AAM, Azlan M, Redzwan NM. Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. *Biomedicines.* 2022;10(2):1–22.
 61. Ottaviani F, Neglia CB, Berti E. Cytokines and adhesion molecules in middle ear cholesteatoma. A role in epithelial growth? *Acta Otolaryngol.* 1999;119(4):462–7.
 62. Kairo AK, Sarwar S, Quadri JA, Singh A, Kumar R, Thakar A, et al. Upregulation of Psoriasin in Cholesteatoma associated with inflammation, bone destruction and severity of disease: Histo-cyto-chemical and ultrastructural studies. *Indian J Biochem Biophys.* 2023;60(8):624–31.
 63. Georgescu SR, Tampa M, Caruntu C, Sarbu MI, Mitran CI, Mitran MI, et al.

- Advances in understanding the immunological pathways in Psoriasis. *Int J Mol Sci.* 2019;20(3):0–17.
64. Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R, et al. IFN- γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. *Sci Transl Med.* 2019;11(511):1–14.
 65. Kutwin M, Migdalska-Sęk M, Brzezińska-Lasota E, Zelga P, Woźniacka A. Analysis of molecular markers as IL-12, IL-22 and IFN- γ in correlation with a clinical course in patients with psoriasis. *Int J Occup Med Environ Health.* 2020;33(5):635–47.
 66. Fathi Gharib A. Assessment of the Level of Interferon-Gamma in the Pathogenesis of Psoriasis. *Ann Immunol Immunother.* 2019;1(1):1–6.
 67. Desember PJ, Anggraeni P. Korelasi antara Kadar IFN- γ Serum dengan Skor PASI pada Psoriasis. *Media Med Muda.* 2017;2(April):137–42.
 68. Davila ML. iScience II CCL27 is a crucial regulator of immune homeostasis of the skin and mucosal tissues. *ISCIENCE.* 2022;25(6):104426.
 69. Rodriguez MM and MC. CCL27 Signaling in the Tumor Microenvironment. In: Birbrair A, editor. *Tumor Microenvironment.* New York: Springer Nature Switzerland; 2021. p. 113–32.
 70. Karnezis Tara. Farnsworth Rae. Harris C Harris. Williams P Steven. Kaiser Karol. Byrne J David. Herles Prad. Macheda L Maria. Shayan Ramin. Zhang Kamu-Fang. Yazar Sezer. Takouridis J Simon. Gerards Craig. Fox Stephen. Achen G Marc and Stacker A Steven. CCL27/CCL28 CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. *Am Assoc Cancer Res.* 2019;79(1):1558–72.
 71. Martinez-Rodriguez M, Thompson AK, Monteagudo C. High CCL27 immunoreactivity in “supratumoral” epidermis correlates with better prognosis in patients with cutaneous malignant melanoma. *J Clin Pathol.* 2017;70(1):15–9.
 72. Wang S, Zhang Z, Peng H, Zeng K. Recent advances on the roles of epidermal growth factor receptor in psoriasis. *Am J Transl Res.* 2019;11(2):520–8.

